Squarepoint’s Allarity Therapeutics ALLR Stock Holding History

Squarepoint’s Portfolio ALLR Stock Details ALLR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,450	Closed	-$14.6K	–	4327
2025 Q2	$14.6K	Buy	+14,450	New	+$13.7K	﹤0.01%	4399

Other funds holding ALLR

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Squarepoint's ALLR Position: Q3 2025 in Review

Squarepoint sold out of Allarity Therapeutics (ALLR) in Q3 2025, closing a stake of 14,450 shares — an estimated $14.6K sold.

Squarepoint first reported a position in ALLR in Q2 2025 and held it in 1 quarter. The position peaked at $14.6K in Q2 2025. 11 funds tracked by Wall St. Rank hold ALLR as of Q3 2025.

Squarepoint reported no remaining Allarity Therapeutics position as of Q3 2025 after selling out during the quarter.
Squarepoint sold 14,450 Allarity Therapeutics shares in Q3 2025, an estimated $14.6K.
Squarepoint first reported a position in Allarity Therapeutics in Q2 2025 and held it in 1 quarter.
Squarepoint's Allarity Therapeutics position peaked at $14.6K in Q2 2025.
11 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.